2. Immunology/Inflammation
  3. CD74
  4. Milatuzumab

Milatuzumab  (Synonyms: hLL1; MEDI-115)

Cat. No.: HY-P99731 Purity: 99.39%
COA
SDS
Technical Support

Milatuzumab (hLL1; MEDI-115) is a humanized anti-CD74 monoclonal antibody. CD74, a integral membrane protein, is associated with the promotion of B-cell growth and survival. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death.

For research use only. We do not sell to patients.

CAS No. : 899796-83-9

Size Price Stock Quantity
Free Sample (100 μg)   Apply Now  
1 mg In-stock
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 4 publication(s) in Google Scholar

Milatuzumab Featured Recommendations:

Milatuzumab Related Antibodies

Top Publications Citing Use of Products

    Milatuzumab purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jun 23:e02838.  [Abstract]

    HCAEC cells were treated with ox-LDL and anti-CD74 antibody (Milatuzumab: 15 mg/kg) for 12 hours, stained with 1 µg/ml WGA-Alexa 488 and CD80, and observed under a confocal microscope.

    Milatuzumab purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jun 23:e02838.  [Abstract]

    Western blot analysis of migratory bodies and M1 macrophage-related markers in HCAEC cells treated with ox-LDL and anti-CD74 antibody (Milatuzumab: 15 mg/kg) was performed.

    Milatuzumab purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jun 23:e02838.  [Abstract]

    Immunofluorescence images showing M1 macrophages and migrasomes in Control, AS, and AS_Anti CD74 (Milatuzumab: 15 mg/kg) groups. Red: WGA‐594 (labeling migrasomes); Green: iNOS (labeling M1 macrophages); Magenta: CD206 (labeling M2 macrophages); Blue: DAPI (nuclei).

    Milatuzumab purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2024 Aug 6;12(8):e009024.  [Abstract]

    Macrophages derived from THP-1 cells treated with anti-CD74 (Milatuzumab) were co-cultured. Phagocytic efficiency was quantified as the percentage of dual-fluorescence-positive macrophages (upper right quadrant).

    Milatuzumab purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2024 Aug 6;12(8):e009024.  [Abstract]

    Flow cytometry was used to detect differences in phagocytic function among the control group, cisplatin group, and combination therapy group with anti-CD74 Ab (5 µg/mL). THP-1-derived macrophages were co-cultured with SiHa cells.

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Milatuzumab (hLL1; MEDI-115) is a humanized anti-CD74 monoclonal antibody. CD74, a integral membrane protein, is associated with the promotion of B-cell growth and survival. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death[1].

    Isotype

    Human IgG1 kappa
    Recommend Isotype Controls
    Species Reactivity

    Human
    IC50 & Target

    CD74
    In Vitro

    Milatuzumaba (5 μg/mL; 8-48 h) enhances cell death in MCL cell lines and primary patient tumor cells[1].
    Milatuzumaba (5 μg/mL; 0.5-2 h) mediates the cytotoxicity partially depending on generation of ROS and loss of mitochondrial transmembrane potential in Jeko, Mino, and SP-53 cells[1].
    Milatuzumaba (5 μg/mL; 4 h) inhibits NF-κB pathway and induces cell apoptosis with independent of caspase cleavage, Bcl-2 family member dysregulation, or induction of autophagy[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Milatuzumab Related Antibodies

    Western Blot Analysis[1]

    Cell Line: Jeko and Mino cells
    Concentration: 5 μg/mL
    Incubation Time: 4 hours
    Result: Insignificant down-regulation of antiapoptotic proteins, such as Bax, Bcl-2, Bcl-xL, and Mcl-1.

    Cell Viability Assay[1]

    Cell Line: MCL cell lines and primarypatient tumor cells
    Concentration: 5 μg/mL
    Incubation Time: 8, 24, and 48 hours
    Result: Resulted in cell death of Jeko, Mino, SP-53, Rec-1, HBL-2, and Granta cells.

    Immunofluorescence[1]

    Cell Line: Jeko, Mino, and SP-53 cells
    Concentration: 5 μg/mL; with or without 10 mM N-acetylcysteine (HY-B0215) for 1.5 h
    Incubation Time: 0.5, 1, 1.5, and 2 hours
    Result: Increased ROS generation as early as 0.5 hours, while peaking at 1 to 1.5 hours and reducing at 2 hours.Therefore, it resulted cell death, but reserved by nonspecific ROS scavenger.
    In Vivo

    Milatuzumaba (15 mg/kg/day; i.p.; once every 3 days) significantly increases the survival rate of female SCID mice bearing Jeko cells. And Milatuzumaba has a synergistic effect with Rituximab (HY-P9913) in mouse model[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Jeko mouse model[1]
    Dosage: 15 mg/kg/day; with or without 15 mg/kg Rituximab
    Administration: Intraperitoneal injection; once every 3 days, starting at day 15 after engraftment
    Result: Resulted the mean survival for the combination treated group of 44.5 days, compared with 33.5 days for Milatuzumaba treated, 28 days for control.
    Clinical Trial
    Gene ID

    972  [NCBI]

    Accession
    Application

    ELISA, FACS, Functional assay
    Conjugated

    Unconjugated
    Reconsititution

    The product can be reconstituted/diluted with sterile PBS or saline.
    Molecular Weight

    145.66 kDa

    CAS No.
    Appearance

    Liquid

    Color

    Colorless to light yellow

    SMILES

    [Milatuzumab]
    Shipping

    Shipping with dry ice.
    Formulation

    Please refer to the lot-specific COA for specific buffer information.
    Storage

    Please store the product under the recommended conditions in the Certificate of Analysis.
    Format
    • Human IgG1 kappa
    Biological Activity
    • Immobilized hu-CD74-ECD-His can bind Milatuzumab. The EC50 for this effect is 3.941 ng/mL.
    • Flow Cytometry analysis of Raji cells labelling CD74 (red) with Milatuzumab (anti-CD74) (HY-P99731). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
    Purity & Documentation

    Purity: 99.39%

    SDS (251 KB)

    COA (232 KB)

    Inhibitory Antibodies User Guide (603 KB)
    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Milatuzumab Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Milatuzumab899796-83-9hLL1 MEDI-115hLL 1hLL-1MEDI115MEDI 115MEDI-115CD74HLA-DR-gammaInvariant polypeptide of major histocompatibility complex, class II antigen-associatedInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Milatuzumab
    Cat. No.:
    HY-P99731
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.